Latest Bare-metal stent Stories
Broad Size Matrix of XIENCE PRIME to be Launched in Europe in the Third Quarter ABBOTT PARK, Ill., June 23 /PRNewswire-FirstCall/ -- Abbott announced today that it has received CE Mark (Conformite Europeenne) for its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
VANCOUVER, May 27 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX) has received approval from the U.S.
NATICK, Mass., May 27 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received approval from the U.S.
NewYork-Presbyterian Hospital and Columbia University Medical Center, together with the Cardiovascular Research Foundation (CRF), announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published in the May 7 New England Journal of Medicine.
VANCOUVER, May 19 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc.
TAXUS(R) Element(TM) Stent now available in select markets worldwide NATICK, Mass., May 19 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the launch of the platinum chromium TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System in select markets worldwide.
- New data to be presented on Abbott's market-leading XIENCE V(R) stent - Educational information available on XIENCE PRIME(TM), Abbott's next-generation drug eluting stent in development BARCELONA, Spain, May 18 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced the company's schedule of major events and news announcements during EuroPCR 2009 in Barcelona, May 19 - 22.
S. Eric Ryan, M.D., Will Discuss the Valecor Platinum(TM) Coronary Stent System on the FiberHalo(TM) Balloon Angioplasty Catheter BURLINGTON, Mass., May 14 /PRNewswire/ -- CorNova Inc. today announced S.
Data from landmark trial provide important insight for physicians in treating heart attack patients NATICK, Mass., May 6 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of results from the HORIZONS AMI trial in this week's issue of the New England Journal of Medicine.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.